131 related articles for article (PubMed ID: 2186854)
1. A controlled trial of bestatin in hydatidiform mole.
Ho PC; Wong LC; Lawton JW; Ma HK
Cancer Immunol Immunother; 1990; 31(3):187-90. PubMed ID: 2186854
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic effect of bestatin on the onset of invasive mole--clinical and fundamental studies.
Asada E; Mano H; Yamada A; Ino K; Ishizuka T; Goto S; Tomoda Y
Biotherapy; 1992; 5(2):145-52. PubMed ID: 1524955
[TBL] [Abstract][Full Text] [Related]
3. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
4. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
6. Serum Human Chorionic Gonadotropin Normogram for the Detection of Gestational Trophoblastic Neoplasia.
Eysbouts Y; Brouwer R; Ottevanger P; Massuger L; Sweep F; Thomas C; van Herwaarden A
Int J Gynecol Cancer; 2017 Jun; 27(5):1035-1041. PubMed ID: 28498241
[TBL] [Abstract][Full Text] [Related]
7. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease.
Duc HN; van Trommel NE; Sweep FC; Massuger LF; Thomas CM
Int J Biol Markers; 2006; 21(1):45-9. PubMed ID: 16711513
[TBL] [Abstract][Full Text] [Related]
9. Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
Chen RJ; Huang SC; Chow SN; Hsieh CY; Hsu HC
Br J Obstet Gynaecol; 1994 Apr; 101(4):330-4. PubMed ID: 8199080
[TBL] [Abstract][Full Text] [Related]
10. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
11. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
12. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
Elmer DB; Granai CO; Ball HG; Curry SL
Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
[TBL] [Abstract][Full Text] [Related]
13. Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus in a retrospective cohort of 141 patients.
Hajri T; Massoud M; Vergne M; Descargues P; Allias F; You B; Lotz JP; Haesebaert J; Bolze PA; Golfier F; Massardier J
Am J Obstet Gynecol; 2024 Mar; 230(3):362.e1-362.e8. PubMed ID: 37722570
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of early-stage nonhydropic mole for diagnosis of persistent trophoblastic disease.
Miyoshi J; Ohba T; Fukunaga M; Katabuchi H
Obstet Gynecol; 2011 Oct; 118(4):847-53. PubMed ID: 21934448
[TBL] [Abstract][Full Text] [Related]
15. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
16. A Case of Rapid Transformation from Hydatidiform Mole to Invasive Mole: The Importance of β-hCG (Human Chorionic Gonadotropin) Serum Levels in Follow-Up Evaluation.
Harsono AB; Hidayat YM; Winarno GNA; Nisa AS; Alkaff FF
Am J Case Rep; 2021 Jun; 22():e931156. PubMed ID: 34127641
[TBL] [Abstract][Full Text] [Related]
17. Immunological parameters in gestational trophoblastic neoplasia.
Ho PC; Mak LW; Lawton JW; Ma HK
J Reprod Immunol; 1980 Feb; 1(5-6):307-19. PubMed ID: 6251216
[TBL] [Abstract][Full Text] [Related]
18. The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study.
Yamamoto E; Trinh TD; Sekiya Y; Tamakoshi K; Nguyen XP; Nishino K; Niimi K; Kotani T; Kajiyama H; Shibata K; Le QT; Kikkawa F
Nagoya J Med Sci; 2020 May; 82(2):183-191. PubMed ID: 32581399
[TBL] [Abstract][Full Text] [Related]
19. Decidual infiltration of FoxP3⁺ regulatory T cells, CD3⁺ T cells, CD56⁺ decidual natural killer cells and Ki-67 trophoblast cells in hydatidiform mole compared to normal and ectopic pregnancies.
Sundara YT; Jordanova ES; Hernowo BS; Gandamihardja S; Fleuren GJ
Mol Med Rep; 2012 Jan; 5(1):275-81. PubMed ID: 22002546
[TBL] [Abstract][Full Text] [Related]
20. Inhibin: a new circulating marker of hydatidiform mole?
Yohkaichiya T; Fukaya T; Hoshiai H; Yajima A; de Kretser DM
BMJ; 1989 Jun; 298(6689):1684-6. PubMed ID: 2503176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
